Publications
Specialty
Search
Lymphoma, Leukemia & Myeloma Network, Oncology
04/09/2024
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.
Oncology
04/09/2024
Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.
EP Lab Digest
04/09/2024
SmartfIRE study evaluates the potential of the investigational Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter to deliver radiofrequency and pulsed field ablation (PFA) for treatment of paroxysmal AFib
Three-month results demonstrate 100% acute success in drug-refractory paroxysmal AFib with high pulmonary vein isolation (PVI) durability
Ablation system uses the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter with the TRUPULSE™ Generator, integrated with CARTO™ 3 System – the world’s leading 3D mapping system
Psych Congress Network
04/09/2024
Medication initiation in patients with attention-deficit/hyperactivity disorder (ADHD) was associated with significantly lower all-cause mortality, according to recent results from an observational nationwide cohort study published in JAMA.
First Report Managed Care
04/09/2024
The US faces a critical maternal health crisis, with high maternal mortality rates exacerbated by COVID-19 and racial disparities. Institutional changes are needed to prevent these largely preventable deaths, and two experts highlight initiatives aimed to address postpartum care inequities.
Neurology
04/09/2024
Are you up-to-date on the latest research? Find out with this quiz!
Pharmacy Learning Network
04/09/2024
US adults hospitalized with respiratory syncytial virus (RSV) were more likely to have cardiopulmonary conditions, undergo longer hospital stays, and need mechanical ventilation compared with those hospitalized with influenza, according to a study published in Clinical Infectious Diseases.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular, EP Lab Digest
04/09/2024
Cathie Biga, MSN, FACC, has became president of the American College of Cardiology as of April 8, 2024, and made history as the organization’s first non-physician president. She will serve a one-year term representing over 56,000 cardiovascular care team members around the world.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/09/2024
“I think that, following this study, many doctors will not find an indication to routinely treat all their patients with beta blockers following a heart attack,” said Troels Yndigegn, MD, interventional cardiologist at Lund University in Sweden and the study’s lead author.
EP Lab Digest
04/09/2024
Boston Scientific Corporation has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation (PFA) Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation (AF).
EP Lab Digest
04/09/2024
New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company’s Deep Learning Technology
Data Shows HeartBeam AI Combined with VCG Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs Found in Leading Smartwatches and Other Wearables
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/09/2024
The trial findings suggest that people with high-risk plaques that are likely to rupture could benefit from PCI as a preemptive measure rather than waiting for a heart attack or other severe reduction in blood flow to occur. The PREVENT trial is the largest study on preventive PCI to date.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/09/2024
“We saw a modest but statistically significant difference in the primary endpoint, but there were no significant differences in other measures of blood pressure, including office systolic or diastolic blood pressure,” said David E. Kandzari, MD, the study’s lead author. “Further, there were unexpectedly large reductions in blood pressure observed in the sham control group that merit further study.”
Pharmacy Learning Network
04/09/2024
In this installment of Talking Therapeutics, Dr Jennings discusses the risks associated with combining selective serotonin inhibitors (SSRIs) and blood thinners.
First Report Managed Care
04/09/2024
“Histologic transformation of indolent lymphoma to aggressive lymphoma, most commonly DLBCL, represents a well-recognized event,” said researchers. “While work in the past decade has shed light on many of the genetic and biological changes of transformation, future investigations are needed to refine therapy approaches to improve patient outcomes.”
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/09/2024
“We can now provide strong data that in this low-risk patient population, you could very safely offer TAVR vs. SAVR,” said Moritz Seiffert, MD, professor of cardiology at BG University Hospital Bergmannsheil, Ruhr University Bochum in Bochum, Germany, and one of the study authors.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/09/2024
The trial focused on patients with angina due to plaque buildup in the coronary arteries that is not adequately controlled with available treatments. The CSR is an hourglass-shaped stent designed to narrow the vein that collects blood from the heart muscle (the coronary sinus) and drive oxygen-rich blood back into areas of the heart muscle that may not be receiving enough blood.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/09/2024
REDUCER-I is a post-market, multi-center, observational study designed to collect long-term outcomes on Shockwave Reducer in a large, ‘real-world’ population of 400 patients.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
04/09/2024
A new analysis of data from the PIONEER AF-PCI clinical trial demonstrates that XARELTO® (rivaroxaban) is associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of clinically significant bleeding [CSB] or major adverse cardiovascular event [MACE]) or rehospitalization compared to warfarin among both elderly and non-elderly patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI)
Pharmacy Learning Network
04/09/2024
The United States Court of Appeals for the Federal Circuit has just revived the case of a female pharmacist who claimed gender discrimination after a male pharmacist was hired at a higher pay.
Current Issue
September 2024
Volume
Issue
Enter Your E-mail
EMSWorld Newsletter
